pharmacodynamics

New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review

Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(4):249-269

Posaconazole is a second generation triazole with a broad spectrum of activity, which first appeared on the market in 2005 in the form of a suspension for oral administration. Despite some progress made in the framework of clinical trials, the …

A Novel View on Common Antibiotics: How to Properly Use Pharmacodynamic Parameters

Clinical Microbiology and Antimicrobial Chemotherapy. 2016; 18(2):125-129

The efficacy of antibacterial therapy is determined by multiple factors, including pharmacokinetic (PK) parameters of the antimicrobial agent. The predictive value of PK parameters has been confirmed in a number of in vivo experiments and clinical …

Anti-Staphylococcal Effects of Telavancin and Vancomycin in In Vitro Simulations of the Antibiotic Pharmacokinetics

Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(1):56-65

Telavancin (TLV) is an investigational lipoglycopeptide with multiple mechanism of action. It exhibits rapid bactericidal activity against gram-positive bacteria, including methicillin-susceptible and -resistant, glycopeptide-intermediate and …

Comparative Pharmacodynamics of Daptomycin and Vancomycin with Staphylococcus aureus in an in vitro Dynamic Model

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):186-192

To compare the pharmacodynamics of daptomycin (DAP) and vancomycin (VAN) as well as killing kinetics of S. aureus with different MICs were studied at widely ranged AUC/MIC ratios. Two clinical isolates, S. aureus 866 (MICDAP 0.35 µ/ml and MICVAN 0.70 …